Suggestions
Sanjeev Thohan
Nonclinical SME (LO to EOP1) - Creatively Prosecuting Science. Funder/Board Member/Entrepreneur/Mentor/Corporate Strategy and Escape Velocity Calculations Scilosopher at large - Pick a topic Opinions are mine alone.
Sanjeev Thohan is a highly experienced research scientist and pharmaceutical industry professional currently serving as the Chief Scientific Officer at LatentSpace Therapeutics.1 With a career spanning over 25 years, Thohan has held various leadership positions in drug development, preclinical research, and toxicology across multiple pharmaceutical companies.
Career Highlights
Thohan's professional journey includes significant roles such as:
- Senior Vice President of Nonclinical Research at Alterome Therapeutics1
- Vice President of Nonclinical Development at Kinnate Biopharma1
- Senior Director of Preclinical Safety at Xeris Pharmaceuticals1
- Research Fellow in Toxicology and Translational Sciences at Novartis1
- Research Director of DMPK/Toxicology Preclinical Development at Exelixis1
Expertise and Contributions
Sanjeev Thohan is known for his expertise in:
- Nonclinical drug development
- Preclinical safety assessment
- Toxicology
- Drug metabolism and pharmacokinetics (DMPK)
- Translational sciences
He describes himself as a "Nonclinical SME (LO to EOP1)" who is "Creatively Prosecuting Science".1 This suggests his focus on nonclinical aspects of drug development from lead optimization (LO) to end of phase 1 (EOP1) clinical trials.
Additional Roles
Beyond his primary career, Thohan is involved in various advisory and entrepreneurial activities:
- Founder of SARx Consulting1
- Scientific Advisory Board Member for Phoenix Molecular Designs and Cogentis Therapeutics1
- Mentor at The Center for Advancing Innovation Inc.1
Sanjeev Thohan's LinkedIn profile demonstrates his extensive experience and ongoing involvement in the pharmaceutical and biotechnology industries, with a particular focus on nonclinical research and drug development.
Highlights
For you Car enthusiasts.
Go to 10 minutes.
Bees might have something.
To understand the potential of Manuka honey as a natural treatment for breast cancer, the research team conducted a series of experiments in mice and in ER-positive MCF-7 and triple-negative MDA-MB-231 breast cancer cell lines, which represent two of the most common types of breast cancer. In these models, oral administration of Manuka honey resulted in a significant reduction in tumor growth compared to control groups. This significant inhibition of tumor progression underscores the honey's potential effectiveness as a treatment for cancer prevention or treatment.
